Blog Posts

PhRMA Pans Government’s Response to J&J’s 340B Rebate Proposal in Letter to HRSA Administrator

PhRMA sent an Oct. 11 letter to HRSA criticizing the agency's opposition to J&J's 340B rebate proposal.
Pharmaceutical Research and Manufacturers of America (PhRMA) expressed “serious concerns” with the federal government’s opposition to Johnson & Johnson’s (J&J’s) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Health Leader Slams J&J Rebate Proposal, Urges Providers to ‘Remain Vigilant’ in Op-Ed

Maureen Testoni, the president and CEO of 340B Health celebrated J&J’s retreat from a 340B rebate proposal in an Oct. 9 RACmonitor op-ed.
The head of an influential 340B hospital advocacy group claimed “victory” in the recent fight against Johnson & Johnson’s (J&J) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Claim Capture by Provider Type: A Compliance and Maximization Guide

SPONSORED CONTENT

Understanding Provider Panels

Provider panels are lists used by 340B Third-Party Administrators (TPAs) to determine which providers’ claims are 340B eligible.  At a minimum, a provider panel should include:

  • Provider’s eligible
Read More »

Providers Raise Caution on Claims Data Submission Requirements After 340B ESP Terms of Use Update Continues to Defer to Manufacturers

Second Sight Solutions updated 340B ESP's terms of use on Oct. 4.
Editor’s Note: An earlier version of this story incorrectly suggested that an Oct. 4 update to 340B ESP’s terms of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Health Centers Urge Federal Appeals Court to Take Their Side in Case Alleging Drug Manufacturer Collusion on Contract Pharmacy Restrictions

Two community health centers argued in a Sept. 30 filing with the U.S. 2nd Circuit Court of Appeals that diabetes drugmakers colluded to place contract pharmacy restrictions.
Two community health centers urged a federal appeals court to overturn the dismissal of their 340B antitrust lawsuit, arguing in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CMS Inaction on IRA-340B Conflicts May Drive ‘Manufacturer-Friendly’ Compliance Models

340B-IRA interactions
CMS has not assumed responsibility for “deduplicating” discounts that arise between the 340B program and the IRA's Medicare drug price negotiations.
Federal regulators’ inaction on the 340B program’s interactions with Medicare drug price negotiations will likely lead drugmakers to pursue “manufacturer-friendly” [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

FQHCs Reinvest 340B Savings in Safety-Net Care, JAMA Study Finds

Federally qualified health centers (FQHCs) appear to use their 340B program savings to enhance safety-net care, according to a new study in JAMA Health Forum.
Federally qualified health centers (FQHCs) appear to use their 340B program savings to enhance safety-net care, according to a new [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

5 Questions to Assess the Effectiveness of Your 340B Pharmacy Program and Position it for Growth

SPONSORED CONTENT

Successful

Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: Orders and Filings in Arkansas, Louisiana, Kansas, Mississippi Maryland, Missouri

Key motions were filed this week in state contract pharmacy litigation in Arkansas, Maryland, Louisiana, Kansas, Missouri, Minnesota and Mississippi.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Head of Drug Industry-Funded Think Tank Backs J&J’s Proposed Rebate Model, Slams Hospitals in Op-Ed

Sally Pipes, the president and CEO of the drug-industry funded Pacific Research Institute, criticized pushback that led Johnson & Johnson to forgo its plans to implement a 340B rebate model in an Oct. 7 Forbes op-ed.
The leader of a right-leaning think tank that’s received funding from the drug industry criticized pushback that led Johnson & [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live